Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Haplotype association analysis of genes within the WNT signalling pathways in diabetic nephropathy

  • David H Kavanagh1,
  • David A Savage2,
  • Christopher C Patterson1,
  • Amy Jayne McKnight1,
  • John K Crean3,
  • Alexander P Maxwell1,
  • Gareth J McKay1Email author and
  • the Warren 3/UK GoKinD Study Group
BMC Nephrology201314:126

DOI: 10.1186/1471-2369-14-126

Received: 4 January 2013

Accepted: 13 June 2013

Published: 18 June 2013

Abstract

Background

Renal interstitial fibrosis and glomerular sclerosis are hallmarks of diabetic nephropathy (DN) and several studies have implicated members of the WNT pathways in these pathological processes. This study comprehensively examined common genetic variation within the WNT pathway for association with DN.

Methods

Genes within the WNT pathways were selected on the basis of nominal significance and consistent direction of effect in the GENIE meta-analysis dataset. Common SNPs and common haplotypes were examined within the selected WNT pathway genes in a white population with type 1 diabetes, discordant for DN (cases: n = 718; controls: n = 749). SNPs were genotyped using Sequenom or Taqman assays. Association analyses were performed using PLINK, to compare allele and haplotype frequencies in cases and controls. Correction for multiple testing was performed by either permutation testing or using false discovery rate.

Results

A logistic regression model including collection centre, duration of diabetes, and average HbA1c as covariates highlighted three SNPs in GSK3B (rs17810235, rs17471, rs334543), two in DAAM1 (rs1253192, rs1252906) and one in NFAT5 (rs17297207) as being significantly (P < 0.05) associated with DN, however these SNPs did not remain significant after correction for multiple testing. Logistic regression of haplotypes, with ESRD as the outcome, and pairwise interaction analyses did not yield any significant results after correction for multiple testing.

Conclusions

These results indicate that both common SNPs and common haplotypes of WNT pathway genes are not strongly associated with DN. However, this does not completely exclude these or the WNT pathways from association with DN, as unidentified rare genetic or copy number variants could still contribute towards the genetic architecture of DN.

Keywords

Diabetic nephropathy WNT signalling pathway Association study End-stage renal disease

Background

Diabetic nephropathy (DN) is a microvascular complication of diabetes and is the most frequent cause of end-stage renal disease (ESRD) in western populations [1]. Renal interstitial fibrosis and glomerular sclerosis are histological hallmarks of DN and several studies have implicated members of the WNT pathways in these pathological processes [29].

The WNT pathways can be subdivided into canonical β-catenin dependent and non-canonical β-catenin independent pathways (Figure 1). Canonical WNT signalling is central to numerous developmental processes and variants discovered within members of this pathway have been implicated in multiple complex diseases such as familial adenomatous polyposis coli, colorectal and hepatocellular cancers, type 2 diabetes and schizophrenia [1014]. Non-canonical WNT signalling is less well defined, in part due to further subdivisions into the WNT/Ca2+ and the WNT planar cell polarity pathways. These pathways have been shown to modulate cytoskeletal reorganisation and activation of the JNK and MAPK signalling pathways [1517], both of which can affect the motility and adherence of the mesangial cell, perturbing the cell's response to dynamic mechanical forces, which is the key function of the mesangial cell.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2369-14-126/MediaObjects/12882_2013_Article_563_Fig1_HTML.jpg
Figure 1

Wnt signalling pathways implicated in diabetic nephropathy. Eleven genes encoding members of the Wnt signalling pathway were prioritized for assessment of association with diabetic nephropathy (AXIN1, CALM3, CTNNB1, DAAM1, DKK2, GSK3B, NFAT5, WNT3, WNT5A, WNT6 and WNT16). (A) Canonical WNT signalling: Some WNT ligands bind to FZD and LRP receptors. DKK internalises the LRP receptors blocking canonical WNT signalling. DVL recruits the AXIN GSK3B destruction complex that is responsible for marking B-catenin for proteosomal degradation. (B) Non-canonical WNT signalling: Certain WNT ligands bind to FZD receptors and elicit the activation of DVL and heterotrimeric G-proteins which in turn can activate DAAM which regulates cytoskeletal organization and focal adhesion dynamics. In addition, activation of CALM regulates the transcription factor NFAT and modulates gene expression.

In vitro epithelial-to-mesenchymal transition (EMT) promotes renal fibrosis and can be induced by TGF-β1 [18], an integrin-linked kinase. Both the canonical WNT pathway and TGF-β1 require activation of β-catenin, in addition to the E-cadherin/β-catenin complexes localised to epithelial intercellular junctions, implicating both β-catenin and the WNT pathway in the regulation of the EMT [19]. Furthermore, GSK3B, the protein responsible for phosphorylation of the β-catenin molecule and its subsequent proteosomal degradation, has been shown to prevent transition to a mesenchymal phenotype in human embryonic stem cells [20]. Several WNT ligands, FZD receptors and β-catenin have all been reported to be differentially expressed in the unilateral ureteral obstructed (UUO) mouse model of renal injury [4]. In addition, Dickkopf-1 (DKK1), a WNT signalling antagonist, was shown to promote hyperglycaemia-induced mesangial matrix expansion in rat mesangial cells [5].

Previously, common variants within four key genes in the WNT pathway have been investigated for association with diabetic nephropathy [21]. In the present study, a more comprehensive assessment was undertaken of common variants in multiple genes within the WNT pathway. Due to the large number of WNT pathway genes (>65), eight potential candidate genes were chosen on the basis of single nucleotide polymorphisms (SNPs) reaching a nominal significance threshold of 0.05 from the meta-analysed Genetics of Nephropathy–an International Effort (GENIE) Consortium dataset (Table 1) [22]. The chosen SNPs also showed a consistent direction of effect in each of the three case–control collections represented by the GENIE Consortium meta-analysed dataset, an international collaboration of three cohorts of type 1 diabetic patients discordant for DN totalling 2916 with nephropathy and 3315 without nephropathy [22]. Three additional genes, CTNNB1, WNT5A and WNT6, were also included within the analysis despite failing to meet the inclusion criteria, on the basis of previous suggestion of their involvement in the pathogenesis of DN. Although the genotyping platforms used to determine the GENIE data provided reasonable coverage across the potential genes of interest, additional informative haplotype tagging SNPs identified through CEU participant data from HapMap offers a more comprehensive evaluation of any potential genetic effect.
Table 1

Genes included within the analysis on the basis of significant association (P < 0.05) within the GENIE meta-analysis[22] and demonstrating a consistent direction of effect across all four cohorts

Chromosome

Position

Gene

SNP

Direction

Allele

P-value

2

219395841

WNT6

rs6436094

- + ??

A

0.19

2

219411542

WNT6

rs730947

- + −+

A

0.12

2

219427976

WNT6

rs7596898

?-??

T

0.73

2

219428221

WNT6

rs940469

+ − ++

T

0.11

2

219429434

WNT6

rs11695967

+ − ++

T

0.11

2

219434742

WNT6

rs10193725

- + −−

T

0.18

2

219440386

WNT6

rs6754599

- + −+

C

0.36

2

219452118

WNT6

rs3806557

+−−-

A

0.95

2

219454805

WNT6

rs10177996

-+++

T

0.95

2

219458990

WNT6

rs2385199

-+++

A

0.94

2

219464627

WNT6

rs7349332

++−−

T

0.61

3

41205327

CTNNB1

rs2691678

-- + −

A

0.32

3

41205658

CTNNB1

rs7630377

-- + −

T

0.58

3

41209520

CTNNB1

rs9859392

++ − +

C

0.39

3

41215181

CTNNB1

rs3864004

----

A

0.38

3

41218746

CTNNB1

rs3915129

++++

T

0.38

3

41229650

CTNNB1

rs2140090

----

T

0.38

3

41236983

CTNNB1

rs1798802

-- + −

A

0.59

3

41237448

CTNNB1

rs13072632

++++

T

0.38

3

41243358

CTNNB1

rs11564447

+ − +−

T

0.41

3

41247085

CTNNB1

rs1880481

----

A

0.37

3

41249076

CTNNB1

rs11564450

++++

C

0.37

3

41254444

CTNNB1

rs4135385

+−−+

A

0.48

3

41259540

CTNNB1

rs9883073

-- + −

A

0.41

3

41262022

CTNNB1

rs11711946

++ − +

T

0.41

3

41270771

CTNNB1

rs11129896

++++

T

0.20

3

55450313

WNT5A

rs815533

-++−

A

0.73

3

55456115

WNT5A

rs3913369

- + −−

T

0.10

3

55462468

WNT5A

rs751194

-- + −

A

0.15

3

55464838

WNT5A

rs1499890

-- + −

A

0.15

3

55466053

WNT5A

rs629537

+−−-

A

0.82

3

55466476

WNT5A

rs503022

+−−-

A

0.76

3

55467366

WNT5A

rs645486

+ − +−

A

0.46

3

55468554

WNT5A

rs476986

--++

A

0.47

3

55469119

WNT5A

rs6792802

-- + −

T

0.07

3

55471300

WNT5A

rs11706227

+ − ++

T

0.07

3

55472993

WNT5A

rs11710229

- + −−

A

0.06

3

55474704

WNT5A

rs12497254

-- + −

A

0.08

3

55475448

WNT5A

rs10865994

-- + −

A

0.07

3

55476215

WNT5A

rs1829556

++ − +

T

0.08

3

55482321

WNT5A

rs556874

-++−

T

0.13

3

55486715

WNT5A

rs472631

+−−-

A

0.73

3

55494897

WNT5A

rs648872

+ − ++

A

0.77

3

55495818

WNT5A

rs566926

+ − ++

T

0.59

3

55506307

WNT5A

rs557077

+−−-

A

0.63

3

55506999

WNT5A

rs1160047

---+

A

0.39

3

121176301

GSK3B

rs6771023

++++

T

0.05

3

121225411

GSK3B

rs6770314

----

A

0.04

3

121232101

GSK3B

rs9851174

----

A

0.04

3

121246776

GSK3B

rs7652172

----

T

0.04

3

121255730

GSK3B

rs968824

++++

A

0.04

3

121273402

GSK3B

rs334536

++++

A

0.05

3

121274994

GSK3B

rs334535

----

T

0.05

3

121292295

GSK3B

rs334559

----

A

0.05

4

108110470

DKK2

rs17509845

++++

A

0.01

7

120715028

WNT16

rs2952556

----

A

<0.01

7

120723242

WNT16

rs10241888

----

A

<0.01

7

120727672

WNT16

rs2707521

----

T

0.01

7

120732453

WNT16

rs1547960

++++

A

<0.01

7

120739818

WNT16

rs10231005

----

A

<0.01

14

58700292

DAAM1

rs6573249

----

T

0.04

14

58728544

DAAM1

rs1252906

++++

A

0.02

14

58735687

DAAM1

rs8016570

++++

T

0.03

14

58744616

DAAM1

rs2146009

++++

A

0.01

14

58748939

DAAM1

rs1252989

++++

A

0.01

14

58753987

DAAM1

rs1270988

++++

A

0.01

14

58795556

DAAM1

rs17095967

++++

A

0.02

14

58800998

DAAM1

rs1253005

----

T

0.04

14

58847352

DAAM1

rs7149497

----

A

0.02

14

58870553

DAAM1

rs1957409

----

A

0.03

16

312598

AXIN1

rs3916990

++++

A

0.03

16

68144622

NFAT5

rs17230557

++++

T

0.02

16

68184592

NFAT5

rs17231138

++++

A

0.01

16

68198345

NFAT5

rs17297088

----

T

0.02

16

68200854

NFAT5

rs17297207

++++

A

0.02

16

68207765

NFAT5

rs17231474

++++

A

0.02

16

68224440

NFAT5

rs6499238

----

T

0.02

16

68262239

NFAT5

rs1437137

----

A

0.02

16

68309874

NFAT5

rs689453

----

T

0.02

17

42221887

WNT3

rs199496

++++

A

0.01

17

42223260

WNT3

rs11655598

++++

C

0.05

17

42223596

WNT3

rs199495

----

A

0.02

17

42229159

WNT3

rs11650531

++++

T

0.04

19

51811750

CALM3

rs11083840

++++

T

0.03

Direction of effect represents that observed in the FinnDiane, UK-ROI, US GoKinD George Washington University, US GoKinD Joslin Diabetes Center.? signifies where a marker failed QC in the original collection and was therefore unavailable for meta-analysis.

The P value presented represents the association of the meta-analysed data from all four GENIE cohorts.

Methods

Participants

Research ethics approval was obtained from the South and West Multicentre Research Ethics Committee (MREC/98/6/71) and Queens University Belfast Research Ethics Committee, and written informed consent obtained prior to participation. All recruited individuals were white, had type 1 diabetes mellitus (T1D) diagnosed before 32 years of age and were born in the UK or Ireland. Cases with nephropathy (n = 718) and controls without nephropathy (n = 749) were from the Warren 3/UK Genetics of Kidneys in Diabetes (GoKinD) and all-Ireland collections [23]. The definition of DN in cases was based on development of persistent proteinuria (>0.5g protein/24h) at least 10 years after diagnosis of T1D, hypertension (blood pressure > 135/85 mmHg or treatment with antihypertensive agents) and associated diabetic retinopathy. Controls were individuals with T1D for at least 15 years with normal urinary albumin excretion rates and no evidence of microalbuminuria on repeated testing (at least 3 assays measuring albumin excretion over a minimum 12 month period, with each test separated by at least 3 months). In addition, control subjects had not been prescribed antihypertensive drug treatment avoiding possible misclassification of diabetic individuals with nephropathy as ‘control phenotypes’ when the use of antihypertensive treatment may have reduced urinary albumin excretion into the normal range. Individuals with micro-albuminuria were excluded from both case and control groups since it is not possible to confidently assign a case or control status to such individuals as their urinary albumin excretion may either regress or progress over time [24].

Haplotype definition, SNP selection and genotyping

A total of 11 genes (AXIN1, CALM3, CTNNB1, DAAM1, DKK2, GSK3B, NFAT5, WNT3, WNT5A, WNT6 and WNT16) were chosen for genotyping (Table 1). SNPs were selected from within these 11 genes to tag common haplotypes (>5% frequency within the HapMap CEU population). Haplotypes for each gene investigated were selected from Phase III, release 2 HapMap (http://www.hapmap.org) CEPH data (Utah residents with ancestry in northern and western Europe; CEU) using Haploview (http://www.broadinstitute.org/haploview) to visualise common haplotypes. Haplotypes were defined using the confidence interval method in Haploview as described in Gabriel et al. [25]. Adjacent haplotypes that had a multi-allelic D-prime of greater 0.9 were combined in an iterative fashion. SNPs were selected using multi-marker tagging for their ability to tag unique haplotypes with r 2  > 0.8 (LOD threshold 3.0). All SNPs had a minor allele frequency (MAF) ≥5%, with quality control filters of genotype call rate ≥95%, and no deviation from Hardy–Weinberg equilibrium (HWE; P < 0.001).

Genotyping was performed by MassARRAY iPLEX (Sequenom, San Diego, CA, USA) or Taqman 5' nuclease (Applied Biosystems, Foster City, CA, USA) assays according to the manufacturers’ instructions. DNA samples were excluded if missing genotypes exceeded 10%. Other quality control measures included parent/offspring trio samples, duplicates on plates, random sample allocation to plates, independent scoring of problematic genotypes by two individuals and re-sequencing of selected DNAs to validate genotypes.

Statistical analysis

Clinical characteristics of cases and controls were compared using the z-test for large independent samples and the χ2 test. Association analyses were performed using PLINK [26]. Initially a χ2 test for trend (1 df) was used with adjustment for collection centre. Logistic regression analysis was then performed on each SNP with terms for potential confounders (collection centre, gender, duration of T1D and HbA1c) included in the model. The level of statistical significance was set at 5% with correction for multiple testing performed by permutation test (n = 100,000). Pairwise interactions between SNPs were tested in the statistical programming package R, using logistic regression to compare models with and without the interaction terms to obtain a likelihood ratio test. The results of the interaction analysis were corrected for multiple testing by false discovery rate (FDR < 5%).

Results and discussion

A total of 90 SNPs were genotyped, 85 using MassARRAY iPLEX Gold technology (Sequenom, San Diego, CA, USA), and five using Taqman 5’ nuclease assay (Applied Biosystems, Foster City, CA, USA) in 719 cases and 748 controls. Quality criteria were applied to the data before association analysis. A total of 35 individuals with more than 10% missing genotype data were removed from the analysis. All SNPs passed the genotyping and Hardy-Weinberg thresholds of 95% and P < 0.001 respectively. No Mendelian errors or inconsistencies between duplicate samples were observed. The final average genotyping rate was 98.9% in 700 cases, and 732 controls.

The clinical characteristics of the DN cases (n = 700) and diabetic controls (n = 732) genotyped in this study, which met quality control filters, are listed in Table 2. There were more males, higher mean HbA1c and blood pressure values (despite the use of antihypertensive treatment) in the case group compared with the control group. All comparisons were significant at P < 0.001 with the exception of age at diagnosis which did not differ significantly between groups. Approximately one quarter of cases (26.6%) had ESRD.
Table 2

Clinical characteristics of the genotyped diabetic nephropathy (DN) cases and diabetic controls

Characteristic

DN Case (n = 700)

Control (n = 732)

Male; n (%)

405 (57.8%)

306 (41.8%)

Age at diagnosis of T1D (yr)

14.7 ± 7.6

15.4 ± 7.9

Duration of T1D (yr)a

33 ± 9.3

28.1 ± 9

HbA1c (%)b

9 ± 1.9

8.6 ± 1.5

Systolic blood pressure (mmHg)b

144.9 ± 20.9

125.1 ± 14.8

Diastolic blood pressure (mmHg)b

81.5 ± 11.4

75.5 ± 7.7

Body mass index (kg/m2)

26.3 ± 4.8

26.1 ± 4.2

Serum cholesterol (mmol/L)

5.3 ± 1.2

5.1 ± 0.9

Serum creatinine (umol/L)c; median (interquartile range)

130 (102–182.5)

92 (78.8 - 105)

Glomerular filtration rate (ml/min/1.73m2)c; median (interquartile range)

47.8 (33.6 - 66.2)

70 (59.3 - 85.5)

End-stage renal disease n (%)

186 (26.6%)

NA

Unless otherwise stated values are mean ± standard deviation.

aCalculated from the dates of diagnosis and recruitment.

bAverage of the three most recent values prior to recruitment.

cExcludes subjects receiving renal replacement therapy (dialysis or transplant).

P < 0.05 for age at diagnosis; P <0.001 for all other comparisons except body mass index.

T1D = type 1 diabetes.

SNPs chosen to tag common haplotypes across the 11 genes selected on the basis of their significant and common direction of effect across the GENIE cohorts (Table 1) [22] were assessed by logistic regression analysis with adjustment for collection centre, gender, duration of T1D and HbA1c (Table 3). Twenty-six putative linkage disequilibrium (LD) blocks were identified across the 11 genes, yielding 110 common haplotypes with an estimated frequency >5%. None of the haplotypes examined were significantly associated with DN at P < 0.01, however eight haplotypes were significantly associated with DN at P < 0.05. Of the eight haplotypes, three were in GSK3B, two in AXIN1, two in DAAM1, and one in NFAT5. However, no significant association between haplotype and DN remained after correction for multiple testing (data not shown).
Table 3

Minor allele frequencies, genotype counts and logistic regression model adjusted for collection centre, gender, duration of type 1 diabetes, and average HbA1c

Chra

Position

Gene

SNP ID

Allele

Case count

MAF

Control count

MAF

ORb

C.I.c

Pd

2

219428221

WNT6

rs940469

[T/C]

24/170/483

0.16

24/170/483

0.18

0.86

0.67 - 1.11

0.25

2

219430908

WNT6

rs690877

[T/C]

56/276/360

0.28

56/276/360

0.27

0.92

0.74 - 1.14

0.43

2

219440386

WNT6

rs6754599

[G/C]

18/166/494

0.15

18/166/494

0.17

0.85

0.65 - 1.11

0.22

2

219458990

WNT6

rs2385199

[G/A]

23/200/471

0.18

23/200/471

0.19

0.90

0.7 - 1.16

0.43

3

41205327

CTNNB1

rs2691678

[C/T]

51/250/390

0.25

51/250/390

0.25

1.01

0.81 - 1.26

0.91

3

41243358

CTNNB1

rs11564447

[G/T]

1/59/634

0.04

1/59/634

0.04

0.91

0.57 - 1.43

0.68

3

41254444

CTNNB1

rs4135385

[G/A]

49/237/398

0.24

49/237/398

0.23

1.04

0.84 - 1.3

0.70

3

55450313

WNT5A

rs815533

[A/G]

22/206/466

0.18

22/206/466

0.17

1.27

0.99 - 1.64

0.06

3

55456115

WNT5A

rs3913369

[T/G]

33/261/394

0.24

33/261/394

0.23

0.91

0.72 - 1.14

0.40

3

55466053

WNT5A

rs629537

[A/G]

11/145/534

0.12

11/145/534

0.13

0.89

0.67 - 1.18

0.40

3

55467090

WNT5A

rs845542

[C/T]

44/272/377

0.26

44/272/377

0.25

1.19

0.95 - 1.49

0.13

3

55494897

WNT5A

rs648872

[T/C]

13/172/501

0.14

13/172/501

0.17

0.86

0.67 - 1.1

0.22

3

55495818

WNT5A

rs566926

[T/G]

49/252/368

0.26

49/252/368

0.27

0.99

0.8 - 1.24

0.96

3

121016036

GSK3B

rs11917714

[T/C]

19/205/470

0.18

19/205/470

0.16

1.02

0.79 - 1.31

0.89

3

121018485

GSK3B

rs11929668

[G/C]

22/170/501

0.15

22/170/501

0.18

0.87

0.67 - 1.12

0.27

3

121133839

GSK3B

rs17204365

[C/T]

2/41/648

0.03

2/41/648

0.03

1.61

0.91 - 2.85

0.10

3

121157741

GSK3B

rs17810235

[T/C]

74/303/312

0.33

74/303/312

0.29

1.33

1.09 - 1.64

0.01

3

121300363

GSK3B

rs17471

[A/T]

3/110/581

0.08

3/110/581

0.09

0.67

0.47 - 0.95

0.02

3

121306727

GSK3B

rs11927974

[A/G]

8/101/584

0.08

8/101/584

0.09

0.98

0.71 - 1.35

0.89

3

121307901

GSK3B

rs334538

[A/G]

22/191/481

0.17

22/191/481

0.19

0.89

0.7 - 1.14

0.35

3

121308854

GSK3B

rs12053912

[T/A]

17/186/485

0.16

17/186/485

0.14

1.21

0.92 - 1.58

0.18

3

121315311

GSK3B

rs334543

[C/A]

66/311/307

0.32

66/311/307

0.35

0.79

0.65 - 0.97

0.02

4

108055760

DKK2

rs429941

[G/A]

53/282/356

0.28

53/282/356

0.28

1.08

0.88 - 1.34

0.46

4

108062942

DKK2

rs10488898

[A/G]

2/77/603

0.06

2/77/603

0.07

0.85

0.58 - 1.24

0.40

4

108065243

DKK2

rs17037102

[A/G]

7/132/526

0.11

7/132/526

0.10

1.17

0.85 - 1.6

0.34

4

108084260

DKK2

rs10488899

[G/T]

42/237/410

0.23

42/237/410

0.21

1.10

0.88 - 1.39

0.40

4

108110470

DKK2

rs17509845

[A/G]

1/66/622

0.05

1/66/622

0.05

1.08

0.69 - 1.7

0.74

4

108120464

DKK2

rs17618172

[G/A]

20/219/445

0.19

20/219/445

0.20

1.01

0.79 - 1.28

0.96

4

108135958

DKK2

rs7690634

[A/T]

9/165/515

0.13

9/165/515

0.12

1.19

0.89 - 1.58

0.24

4

108165736

DKK2

rs4956277

[C/A]

30/246/396

0.23

30/246/396

0.24

0.94

0.75 - 1.17

0.58

4

108170809

DKK2

rs10021344

[G/A]

150/357/185

0.47

150/357/185

0.48

0.99

0.82 - 1.19

0.88

4

108173328

DKK2

rs956137

[A/C]

4/111/577

0.09

4/111/577

0.08

1.28

0.92 - 1.8

0.15

4

108173463

DKK2

rs6827902

[C/A]

28/237/416

0.22

28/237/416

0.21

1.15

0.91 - 1.45

0.23

4

108181414

DKK2

rs6823507

[C/T]

1/88/593

0.07

1/88/593

0.08

0.87

0.6 - 1.26

0.46

4

108185493

DKK2

rs419178

[C/T]

38/272/379

0.25

38/272/379

0.27

0.86

0.69 - 1.07

0.17

4

108199999

DKK2

rs398093

[T/C]

12/138/510

0.12

12/138/510

0.12

1.09

0.81 - 1.46

0.58

4

108200154

DKK2

rs17510191

[C/T]

20/251/423

0.21

20/251/423

0.18

1.13

0.89 - 1.43

0.31

7

120727672

WNT16

rs2707521

[T/C]

103/338/239

0.40

103/338/239

0.41

0.90

0.74 - 1.1

0.32

7

120738146

WNT16

rs13247600

[C/G]

3/81/610

0.06

3/81/610

0.07

1.08

0.74 - 1.57

0.69

7

120738380

WNT16

rs2707520

[G/T]

166/340/183

0.49

166/340/183

0.49

1.12

0.92 - 1.35

0.25

7

120741508

WNT16

rs983926

[A/G]

6/101/587

0.08

6/101/587

0.09

0.93

0.67 - 1.3

0.68

7

120751201

WNT16

rs3757552

[C/T]

9/151/534

0.12

9/151/534

0.12

0.89

0.67 - 1.19

0.44

7

120762001

WNT16

rs3801387

[C/T]

69/283/340

0.30

69/283/340

0.29

1.00

0.81 - 1.23

0.99

7

120774586

WNT16

rs2707461

[T/C]

18/187/489

0.16

18/187/489

0.17

0.98

0.77 - 1.26

0.89

14

58696138

DAAM1

rs8016068

[T/C]

4/176/514

0.13

4/176/514

0.12

1.09

0.81 - 1.47

0.57

14

58713714

DAAM1

rs17095819

[G/A]

15/185/477

0.16

15/185/477

0.13

1.28

0.96 - 1.71

0.09

14

58728544

DAAM1

rs1252906

[G/T]

19/164/511

0.15

19/164/511

0.18

0.75

0.58 - 0.97

0.03

14

58826755

DAAM1

rs7155987

[T/C]

18/180/496

0.16

18/180/496

0.14

1.10

0.84 - 1.44

0.48

14

58833620

DAAM1

rs12878138

[T/C]

2/99/593

0.07

2/99/593

0.07

0.96

0.67 - 1.39

0.84

14

58861382

DAAM1

rs941882

[C/A]

40/238/416

0.23

40/238/416

0.23

1.03

0.82 - 1.28

0.82

14

58885779

DAAM1

rs17834014

[G/A]

3/86/605

0.07

3/86/605

0.08

0.97

0.67 - 1.42

0.88

14

58886484

DAAM1

rs12880248

[A/G]

12/177/505

0.14

12/177/505

0.14

1.06

0.8 - 1.39

0.70

14

58889427

DAAM1

rs12878070

[G/T]

150/334/210

0.46

150/334/210

0.42

1.10

0.91 - 1.32

0.33

14

58908520

DAAM1

rs17096179

[C/A]

5/104/585

0.08

5/104/585

0.09

0.88

0.63 - 1.24

0.47

14

58913159

DAAM1

rs1253192

[A/G]

5/80/609

0.06

5/80/609

0.09

0.65

0.46 - 0.93

0.02

16

275374

AXIN1

rs2685127

[T/C]

7/157/529

0.12

7/157/529

0.13

1.02

0.76 - 1.36

0.92

16

276397

AXIN1

rs400037

[T/C]

32/243/410

0.22

32/243/410

0.22

0.97

0.77 - 1.21

0.77

16

281080

AXIN1

rs12925669

[A/G]

22/171/501

0.15

22/171/501

0.16

1.06

0.82 - 1.37

0.65

16

289294

AXIN1

rs214246

[C/T]

148/349/196

0.47

148/349/196

0.49

0.93

0.77 - 1.12

0.45

16

303385

AXIN1

rs12930863

[C/T]

20/175/490

0.16

20/175/490

0.16

1.05

0.81 - 1.36

0.70

16

313818

AXIN1

rs11646942

[A/C]

51/261/355

0.27

51/261/355

0.31

0.89

0.72 - 1.1

0.29

16

333343

AXIN1

rs395901

[A/G]

7/115/569

0.09

7/115/569

0.09

0.82

0.6 - 1.14

0.24

16

336265

AXIN1

rs1805105

[A/G]

67/310/284

0.34

67/310/284

0.31

1.19

0.97 - 1.47

0.10

16

68112382

NFAT5

rs12921716

[A/G]

6/113/575

0.09

6/113/575

0.08

0.95

0.68 - 1.32

0.75

16

68117197

NFAT5

rs4783720

[C/T]

22/184/488

0.16

22/184/488

0.15

1.10

0.85 - 1.43

0.47

16

68200854

NFAT5

rs17297207

[G/A]

3/69/612

0.05

3/69/612

0.07

0.66

0.44 - 0.98

0.04

16

68203623

NFAT5

rs11639947

[T/C]

22/183/467

0.17

22/183/467

0.21

0.80

0.63 - 1.02

0.07

16

68281721

NFAT5

rs1064825

[A/G]

0/74/619

0.05

0/74/619

0.06

0.84

0.55 - 1.28

0.42

16

68290961

NFAT5

rs7359336

[G/A]

128/329/227

0.43

128/329/227

0.41

1.04

0.86 - 1.26

0.69

17

42163544

WNT3

rs35937770

[A/G]

83/321/283

0.35

83/321/283

0.35

0.99

0.81 - 1.21

0.90

17

42188384

WNT3

rs35732828

[A/C]

19/200/466

0.17

19/200/466

0.17

1.05

0.81 - 1.35

0.71

17

42209035

WNT3

rs199520

[G/A]

38/237/419

0.23

38/237/419

0.22

1.04

0.83 - 1.3

0.75

17

42221887

WNT3

rs199496

[A/G]

5/117/569

0.09

5/117/569

0.07

1.11

0.78 - 1.58

0.56

17

42221965

WNT3

rs11658976

[G/A]

129/338/227

0.43

129/338/227

0.42

1.03

0.85 - 1.25

0.74

17

42223260

WNT3

rs11655598

[G/C]

46/249/387

0.25

46/249/387

0.29

0.94

0.76 - 1.16

0.57

17

42223353

WNT3

rs12452064

[A/G]

147/322/211

0.45

147/322/211

0.43

1.08

0.9 - 1.3

0.42

17

42224733

WNT3

rs10432043

[T/C]

86/301/284

0.35

86/301/284

0.33

1.07

0.88 - 1.31

0.50

17

42234514

WNT3

rs7207916

[A/G]

113/313/267

0.39

113/313/267

0.43

0.93

0.77 - 1.12

0.43

17

42243374

WNT3

rs11079737

[A/G]

54/268/338

0.28

54/268/338

0.27

1.12

0.91 - 1.38

0.30

17

42259048

WNT3

rs11079738

[G/A]

143/362/188

0.47

143/362/188

0.47

1.02

0.84 - 1.23

0.88

17

42261948

WNT3

rs8069437

[T/C]

35/225/433

0.21

35/225/433

0.23

0.85

0.68 - 1.07

0.16

19

51775092

CALM3

rs8103534

[C/T]

63/298/333

0.31

63/298/333

0.31

0.96

0.78 - 1.18

0.67

19

51781925

CALM3

rs4274528

[T/C]

7/144/542

0.11

7/144/542

0.12

1.17

0.87 - 1.57

0.31

19

51790267

CALM3

rs7260181

[C/T]

146/355/193

0.47

146/355/193

0.46

1.08

0.89 - 1.31

0.43

19

51798474

CALM3

rs4380146

[G/T]

69/284/327

0.31

69/284/327

0.32

1.03

0.84 - 1.26

0.76

19

51800325

CALM3

rs11671131

[C/T]

12/167/513

0.14

12/167/513

0.14

0.87

0.67 - 1.14

0.32

19

51804580

CALM3

rs710889

[A/G]

94/315/285

0.36

94/315/285

0.36

0.93

0.76 - 1.13

0.47

19

51804978

CALM3

rs10405893

[A/G]

5/153/535

0.12

5/153/535

0.11

1.25

0.92 - 1.69

0.16

19

51811750

CALM3

rs11083840

[G/T]

118/341/235

0.42

118/341/235

0.44

0.91

0.75 - 1.1

0.32

19

51811873

CALM3

rs11083841

[G/A]

26/181/457

0.18

26/181/457

0.16

1.15

0.9 - 1.47

0.26

aChr = Chromosome.

bOR = Odds Ratio.

cC.I. = 95% Confidence Interval.

dP-value, not corrected for multiple testing.

In a single marker analysis, adjusted by collection centre, no SNPs were associated with DN at P < 0.01 (the significance threshold set was corrected for multiple testing), however five SNPs, rs17810235, rs11639947, rs11646942, rs17095819, and rs17510191 in GSK3B, NFAT5, AXIN1, DAAM1, DKK2 had P-values <0.05 as shown in Table 4a. Logistic regression analyses were performed with adjustment for collection centre, gender, duration of T1D, and average HbA1c as covariates in the model. The most significant association was reported for rs17810235 in GSK3B (Table 4b; P = 0.006). Five additional SNPs demonstrated a P <0.05, although they were not supported in the univariate analysis alone. Although limited in power, a subgroup analysis defined by comparison of ESRD as the primary phenotype versus non-ESRD, identified two significantly associated SNPs, rs1253192 and rs11079737 in DAAM1 and WNT3 respectively with P = 0.009, although neither association survived correction for multiple testing (Table 4c).
Table 4

Most significant results from logistic regression analyses

a. Single SNP analysis for diabetic nephropathy

Gene

SNP

a OR

b C.I.

c P

GSK3B

rs17810235

1.23

1.03 - 1.45

0.022

NFAT5

rs11639947

0.79

0.64 - 0.97

0.023

AXIN1

rs11646942

0.82

0.68 - 0.97

0.026

DAAM1

rs17095819

1.27

1.01 - 1.59

0.045

DKK2

rs17510191

1.23

1.01 - 1.49

0.047

b. Adjusted logistic regression analysis for diabetic nephropathy

GSK3B

rs17810235

1.33

1.09 - 1.64

0.006

DAAM1

rs1253192

0.65

0.46 - 0.93

0.018

GSK3B

rs17471

0.67

0.47 - 0.95

0.025

GSK3B

rs334543

0.79

0.65 - 0.97

0.025

DAAM1

rs1252906

0.75

0.58 - 0.97

0.027

NFAT5

rs17297207

0.66

0.44 - 0.98

0.040

c. Adjusted logistic regression analysis for end-stage renal disease

WNT3

rs11079737

1.50

1.13 - 1.98

0.005

DAAM1

rs1253192

0.43

0.23 - 0.81

0.009

DAAM1

rs941882

1.45

1.08 - 1.94

0.013

CALM3

rs8103534

0.68

0.50 - 0.92

0.013

DKK2

rs6827902

1.47

1.08 - 1.99

0.015

DAAM1

rs1252906

0.60

0.40 - 0.91

0.015

WNT3

rs11079738

1.33

1.02 - 1.74

0.035

DAAM1

rs7155987

1.43

1.02 - 2.02

0.040

DAAM1

rs17834014

1.61

1.01 - 2.55

0.045

WNT6

rs940469

0.68

0.47 - 0.99

0.046

aOR: Odds Ratio.

bC.I.: 95% Confidence Intervals.

cP: value adjusted for collection centre, gender, duration of type 1 diabetes, and average HbA1c as covariates; not corrected for multiple testing.

Assessment of 4005 pair-wise interactions between the 90 SNPs was performed by logistic regression analyses with adjustment for collection centre, gender, duration of T1D, and HbA1c. The χ2 likelihood ratio tests (Table 5) identified four interaction terms as nominally significant between SNPs in AXIN1, DAAM1, DKK2, WNT3 and WNT6. However, these interactions were not significant following correction for multiple testing by FDR P < 5%.
Table 5

Interaction analyses with adjustment for covariates

Gene1

SNP1

Gene2

SNP2

P

aP

AXIN1

rs395901

AXIN1

rs1805105

8.40E-05

0.39

WNT6

rs690877

WNT3

rs199496

0.00043

0.58

DAAM1

rs17834014

WNT3

rs199496

0.00049

0.70

DKK2

rs398093

DAAM1

rs17834014

0.00072

0.73

GSK3B

rs11917714

DKK2

rs17510191

0.00096

0.73

aCorrected for multiple testing by False Discovery Rate.

There is an increasing body of evidence to suggest that modulation of the WNT pathways may play a role in the development of DN. β-catenin and TCF/LEF have been shown to directly induce the expression of the cyclic nucleotide phosphodiesterase CNP, a regulator of fibroblast proliferation and activation [2]. The expression of secreted frizzled-related protein 4 (SFRP4), an inhibitor of WNT signalling, is decreased following UUO. This decrease is concomitant with increased levels of WNT/β-catenin signalling, in tubular and interstitial cells, along with increased fibronectin and smooth muscle actin, both markers of fibrosis. Introduction of recombinant SFRP4 reduced the markers of fibrosis and WNT/β-catenin signalling. Furthermore E-cadherin expression was partially maintained by treatment with recombinant SFRP4, and the number of myofibroblasts decreased [3]. DKK1 is shown to be increased in mesangial cells in response to stimulation with high concentrations of glucose [5]. In addition high concentrations of glucose decreased WNT signalling and increased TGF-β1 and fibronectin expression in mesangial cells. Transfection of WNT4, WNT5a, GSK3β and β-catenin ameliorated the TGF-β1-induced fibrosis [8]. Cultured podocytes with stabilised β-catenin are less motile and less adherent to the extracellular matrix whereas deletion of β-catenin rendered the cells more susceptible to apoptosis [6].

Gene-based assessments of association are increasingly been viewed as a useful complement to genome-wide association studies (GWAS) [27]. The gene-based approach reduces the problems associated with multiple testing that inhibit GWAS by reducing the number of statistical tests under consideration. Our study has adopted a two stage approach to evaluate common variants in all WNT pathway members in relation to DN. SNPs located in genes implicated in the WNT pathways that failed to demonstrate significant association and direction of effect across all GENIE cohorts [22] were excluded at the first step. WNT pathway members that demonstrated significant association and direction of effect with DN across the three GENIE case–control collections were then evaluated more meticulously through refined genotyping of haplotype tagging SNPs. This approach offers a more comprehensive assessment of common variants across the WNT pathways in comparison to previously published studies. Univariate SNP analysis failed to identify any association with DN. Multivariate regression analyses of common haplotypic structure also failed to reveal any associations that remained significant after correction for multiple testing. All possible combinations of pair-wise SNP-SNP interactions were tested as an interaction term in a logistic regression model. Due to the large number of tests, and the unsuitability of permutations as a correction for multiple testing in interaction analyses, the false discovery rate method was used, although no associations remained significant after correction.

There are a number of inherent limitations associated with using a restricted number of SNPs across a chosen set of genes [28]: (1) identification of association does not necessarily equate to functional significance given the concept of LD. (2) assessing one or two SNPs per gene may provide inadequate representation of the genetic architecture at that locus. (3) patterns of LD can vary significantly within and between different populations and therefore a significant association in one population may not necessarily translate across all populations. In addition, common genetic loci are likely to explain only a proportion of the variation contributing to the phenotype under consideration. Evidence in support of rare variants with potentially large individual effect size is currently under investigation in DN. Since our study focused only on common variants, untyped, highly penetrant rare variants in these genes could also contribute to DN. The size of our study was such that it had 90% power to detect variants with odds ratios of 1.69, 1.50, 1.44, and 1.42 and MAF of 10%, 20%, 30%, and 40%, respectively. Sample sizes of the magnitude required to detect variants present in the population with a lower frequency or with a smaller effect size were not available for analysis and would require international, multicentre collaborative efforts. Future amalgamation of independent cohorts with similar DN phenotypes will enable a more robust evaluation of such loci. In addition, other factors such as copy number variation or indeed epigenetic mechanisms (e.g. DNA methylation, histone modification and microRNAs) may also modify gene function and/or expression profiles affecting these pathways and modulating disease risk accordingly.

Conclusion

There was no association observed between DN and either common variants or haplotypes among any of the genes associated with the WNT pathway. It is unlikely that common variants located within WNT pathway genes have a major role in the underlying genetics of DN. Further investigation of rare variants, copy number variants or epigenetic mechanisms, in WNT pathway members may identify potential risk factors that contribute to the genetic susceptibility of DN, in addition to identifying potential therapeutic targets for this disease.

Declarations

Acknowledgements

David H Kavanagh is supported by a Northern Ireland Kidney Research Fund (NIKRF) PhD studentship. We thank the NIKRF and Northern Ireland Research and Development Office for supporting this work. We thank Dr Denise Sadlier, University College Dublin, for providing DNA samples from cases and controls from the Republic of Ireland. The Warren 3 / UK GoKinD Study Group was jointly funded by Diabetes UK and the Juvenile Diabetes Research Foundation and includes the following individuals: Belfast: Professor A. P. Maxwell, Dr A. J. McKnight, Dr D. A. Savage; Edinburgh: Dr J. Walker; London: Dr S. Thomas, Professor G. C. Viberti; Manchester: Professor A. J. M. Boulton; Newcastle: Professor S. Marshall; Plymouth: Professor A. G. Demaine and Dr B. A. Millward; Swansea: Professor S. C. Bain. We also thank the Genetics of Nephropathy – an International Effort (GENIE) study group for provision of data. GENIE was jointly funded by NIH NIDDK R01 DK081923, The Northern Ireland Research Development office and Science Foundation Ireland US-Ireland R&D partnership, and The Health Research Board Ireland.

Authors’ Affiliations

(1)
Nephrology Research Group, Centre for Public Health, Queen’s University Belfast
(2)
Histocompatibility & Immunogenetics Laboratory, Belfast Health and Social Care Trust, Belfast City Hospital
(3)
Conway Institute, University College Dublin

References

  1. Gilg J, Castledine C, Fogarty D: Chapter 1 UK RRT incidence in 2010: national and centre-specific analyses. Nephron Clin Pract. 2012, 120 (Suppl 1): c1-27.View ArticlePubMedGoogle Scholar
  2. Surendran K, Simon TC: CNP gene expression is activated by Wnt signaling and correlates with Wnt4 expression during renal injury. Am J Physiol Renal Physiol. 2003, 284: F653-662.View ArticlePubMedGoogle Scholar
  3. Surendran K, Schiavi S, Hruska KA: Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol. 2005, 16: 2373-2384. 10.1681/ASN.2004110949.View ArticlePubMedGoogle Scholar
  4. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y: Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol. 2009, 20: 765-776. 10.1681/ASN.2008060566.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Lin CL, Wang JY, Ko JY, Huang YT, Kuo YH, Wang FS: Dickkopf-1 promotes hyperglycemia-induced accumulation of mesangial matrix and renal dysfunction. J Am Soc Nephrol. 2010, 21: 124-135. 10.1681/ASN.2008101059.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Kato H, Gruenwald A, Suh JH, et al: Wnt/β-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Biol Chem. 2011, 286: 26003-26015. 10.1074/jbc.M111.223164.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Rooney B, O’Donovan H, Gaffney A, et al: CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy. FEBS Lett. 2011, 585: 531-538. 10.1016/j.febslet.2011.01.004.View ArticlePubMedGoogle Scholar
  8. Ho C, Lee PH, Hsu YC, Wang FS, Huang YT, Lin CL: Sustained Wnt/β-Catenin Signaling Rescues High Glucose Induction of Transforming Growth Factor-β1-Mediated Renal Fibrosis. Am J Med Sci. 2012, 344: 374-382.View ArticlePubMedGoogle Scholar
  9. Zhou T, He X, Cheng R, et al: Implication of dysregulation of the canonical wingless-type MMTV integration site (WNT) pathway in diabetic nephropathy. Diabetologia. 2012, 55: 255-266. 10.1007/s00125-011-2314-2.View ArticlePubMedGoogle Scholar
  10. Hart M, Concordet JP, Lassot I, et al: The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol. 1999, 9: 207-210. 10.1016/S0960-9822(99)80091-8.View ArticlePubMedGoogle Scholar
  11. Polakis P: Wnt signaling and cancer. Genes Dev. 2000, 14: 1837-1851.PubMedGoogle Scholar
  12. Grant SFA, Thorleifsson G, Reynisdottir I, et al: Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006, 38: 320-323. 10.1038/ng1732.View ArticlePubMedGoogle Scholar
  13. Saxena R, Gianniny L, Burtt NP, et al: Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes. 2006, 55: 2890-2895. 10.2337/db06-0381.View ArticlePubMedGoogle Scholar
  14. Steinberg S, de Jong S, Andreassen OA, et al: Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Human Mol Genet. 2011, 20: 4076-4081. 10.1093/hmg/ddr325.View ArticleGoogle Scholar
  15. Habas R, Dawid IB, He X: Coactivation of Rac and Rho by Wnt/Frizzled signaling is required for vertebrate gastrulation. Gen Dev. 2003, 17: 295-309. 10.1101/gad.1022203.View ArticleGoogle Scholar
  16. Veeman MT, Axelrod JD, Moon RT: A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev Cell. 2003, 5: 367-377. 10.1016/S1534-5807(03)00266-1.View ArticlePubMedGoogle Scholar
  17. Habas R, Dawid IB: Dishevelled and Wnt signaling: is the nucleus the final frontier?. J Biol. 2005, 4: 2-10.1186/jbiol22.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Liu Y: New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010, 21: 212-222. 10.1681/ASN.2008121226.View ArticlePubMedGoogle Scholar
  19. Ivanova L, Butt MJ, Matsell DG: Mesenchymal transition in kidney collecting duct epithelial cells. Am J Physiol Renal Physiol. 2008, 294: F1238-1248. 10.1152/ajprenal.00326.2007.View ArticlePubMedGoogle Scholar
  20. Ullmann U, Gilles C, De Rycke M, Van de Velde H, Sermon K, Liebaers I: GSK-3-specific inhibitor-supplemented hESC medium prevents the epithelial-mesenchymal transition process and the up-regulation of matrix metalloproteinases in hESCs cultured in feeder-free conditions. Mol Hum Reprod. 2008, 14: 169-179. 10.1093/molehr/gan001.View ArticlePubMedGoogle Scholar
  21. Kavanagh DH, Savage DA, Patterson CC, et al: Association analysis of canonical Wnt signalling genes in diabetic nephropathy. PLoS One. 2011, 6: e23904-10.1371/journal.pone.0023904.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Sandholm N, Salem RM, McKnight AJ, et al: New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes. PLoS Genet. 2012, 8: e1002921-10.1371/journal.pgen.1002921.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Kavanagh D, McKay GJ, Patterson CC, McKnight AJ, Maxwell AP, Savage DA: Association analysis of Notch pathway signalling genes in diabetic nephropathy. Diabetologia. 2011, 54: 334-338. 10.1007/s00125-010-1978-3.View ArticlePubMedGoogle Scholar
  24. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS: Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003, 348: 2285-2293. 10.1056/NEJMoa021835.View ArticlePubMedGoogle Scholar
  25. Gabriel SB, Schaffner SF, Nguyen H, et al: The structure of haplotype blocks in the human genome. Science. 2002, 296: 2225-2229. 10.1126/science.1069424.View ArticlePubMedGoogle Scholar
  26. Purcell S, Neale B, Todd-Brown K, et al: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Human Genet. 2007, 81: 559-575. 10.1086/519795.View ArticleGoogle Scholar
  27. Liu JZ, McRae AF, Nyholt DR, et al: A versatile gene-based test for genome-wide association studies. Am J Hum Genet. 2010, 87: 139-145. 10.1016/j.ajhg.2010.06.009.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Cardon LR, Bell JI: Association study designs for complex diseases. Nat Rev Genet. 2001, 2: 91-99.View ArticlePubMedGoogle Scholar
  29. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/14/126/prepub

Copyright

© Kavanagh et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement